Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Monday

Cue Biopharma (NASDAQ:CUE) will likely be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.00 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 7:00 AM ET.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Monday, March 16th. The company reported $0.01 EPS for the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%. The firm had revenue of $21.94 million during the quarter. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Stock Down 4.6%

NASDAQ:CUE opened at $0.24 on Friday. The stock has a market capitalization of $23.29 million, a price-to-earnings ratio of -0.75 and a beta of 1.51. Cue Biopharma has a 52 week low of $0.22 and a 52 week high of $1.05. The firm has a 50 day moving average of $0.31 and a 200 day moving average of $0.49.

Hedge Funds Weigh In On Cue Biopharma

Hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC raised its position in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after purchasing an additional 93,333 shares during the last quarter. Stifel Financial Corp grew its position in Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Cue Biopharma during the 3rd quarter valued at approximately $62,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.